Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

JPM 2021: Medtronic, Biogen, Edwards LifeSciences, Guardant Health, Illumina

Jan 12 2021

• By Reed Miller and Marion Webb

J.P. Morgan Daily Notebook - Day 1

Related Content

J.P. Morgan 2021: The Show Must Go On

Jan 07 2021

Illumina Will Pay $8Bn To Buy Back Cancer Screening Start-Up Grail

Sep 21 2020

Grail Files For $100M IPO, Plans To Launch Multi-Cancer Early Detection Test In 2021

Sep 09 2020

Guardant Health Expects FDA Approval Of Liquid Biopsy Test Will Strengthen Coverage, Adoption

Aug 11 2020

Edwards Returns To Growth In The Third Quarter

Oct 22 2020

Medtronic Lays Out Plans To Achieve 5%+ Annual Growth

Oct 15 2020

Grail Starts PATHFINDER Trial To Evaluate Multi-Cancer Blood Test For Early Cancer Detection

Feb 20 2020

Related Companies

Medtronic plc

Apple Inc.

Biogen, Inc.

Edwards Lifesciences Corp.

Illumina, Inc.

Merck & Co., Inc.

Myriad Genetics, Inc.

GRAIL Inc.

Amgen, Inc.

AstraZeneca LP

Additional Topics

Coronavirus COVID-19 Digital Health Financing Innovation M & A Commercial Research & Development Cancer Cardiovascular Infectious Diseases Diagnostics Neurology Surgical Procedures Medical Device

More from Digital Technologies

More from Medtech Insight

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window